These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19110087)

  • 21. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.
    Insull W
    Am J Med; 2009 Jan; 122(1 Suppl):S3-S14. PubMed ID: 19110086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
    Bays H
    Am J Cardiol; 2006 Aug; 98(4A):71i-76i. PubMed ID: 16919519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dyslipidemia management in patients with impaired glucose tolerance].
    Asano M; Yamada N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():538-42. PubMed ID: 15779437
    [No Abstract]   [Full Text] [Related]  

  • 26. The power of statins: aggressive lipid lowering.
    Jones PH
    Postgrad Med; 2002 Oct; 112(4 Suppl):23-30. PubMed ID: 19667597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging therapies for atherosclerosis prevention and management.
    Chyu KY; Shah PK
    Cardiol Clin; 2011 Feb; 29(1):123-35. PubMed ID: 21257104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High HDL may not protect the heart. Concentrate on lowering LDL for now, experts advise.
    Harv Heart Lett; 2012 Sep; 23(1):6. PubMed ID: 23097807
    [No Abstract]   [Full Text] [Related]  

  • 33. [Cholesterol metabolism modulators in future drug therapy for atherosclerosis].
    Morozova S; Suc-Royer I; Auwerx J
    Med Sci (Paris); 2005 Dec; 21 Spec No():53-8. PubMed ID: 16598906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
    Santos-Gallego CG; Ibanez B; Badimon JJ
    Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.
    Grover SA; Kaouache M; Joseph L; Barter P; Davignon J
    Arch Intern Med; 2009 Oct; 169(19):1775-80. PubMed ID: 19858435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
    Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesterol and coronary events. The current thinking.
    Jones PH
    Postgrad Med; 2003 Apr; 113(4 Suppl):5-14. PubMed ID: 19667618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations.
    Lavie CJ
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):29-33. PubMed ID: 15133427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of lipid-altering therapies on ventricular arrhythmias and sudden cardiac death.
    Majmudar MD; Tompkins C; Bachmann JM; Blumenthal RS; Marine JE
    Cardiol Rev; 2009; 17(2):60-9. PubMed ID: 19367147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia.
    Almutairi F; Peterson TC; Molinari M; Walsh MJ; Alwayn I; Peltekian KM
    Liver Transpl; 2009 May; 15(5):504-8. PubMed ID: 19399742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.